Spirulina and MHC Class II Antigen Presentation: Dendritic Cell Maturation, Invariant Chain, and Adaptive Immunity Priming

MHC Class II Structure and Peptide-Binding Groove

MHC class II molecules (encoded by HLA-DR, HLA-DQ, and HLA-DP in humans; H-2A and H-2E in mice) are heterodimeric transmembrane glycoproteins consisting of a non-covalently associated alpha-chain (33–34 kDa) and beta-chain (26–29 kDa), each contributing two extracellular domains. The membrane-distal alpha1 and beta1 domains form the peptide-binding groove, which is open at both ends — unlike MHC class I, which is closed — allowing it to accommodate peptides typically 13–25 amino acids in length that extend beyond the groove's edges. The peptide contacts nine pockets (P1 through P9) within the groove; anchor residues at P1 and P4 in particular make critical contacts with polymorphic residues defining HLA allele-specific peptide binding preferences. Once a stable peptide-MHC II (pMHC-II) complex forms, it is remarkably long-lived (half-life of days at the cell surface), enabling sustained interaction with T cell receptors during the immunological synapse. MHC-II expression is constitutive on professional antigen-presenting cells — dendritic cells, macrophages, and B cells — and is inducible by IFN-gamma on many other cell types including endothelium, thyroid epithelium, and intestinal epithelial cells.

Invariant Chain (Ii/CD74): ER Chaperoning and CLIP Generation

Newly synthesised MHC-II alphabeta dimers in the endoplasmic reticulum (ER) associate with three copies of the invariant chain (Ii; CD74), forming a nonameric (alphabeta-Ii)3 complex. The invariant chain serves three functions simultaneously: its CLIP (class II- associated Ii peptide) region (residues 81–104 in human Ii) occupies the peptide-binding groove, preventing premature loading of endogenous ER peptides (which would misdirect exogenous antigen presentation); its trimerisation domain promotes correct alphabeta dimerisation and complex stability; and its cytoplasmic dileucine targeting motif (DXXLL) directs the complex through the Golgi to late endosomes/lysosomes (MHC-II compartments; MIIC). In MIICs, the acidic pH (4.5–5.5) optimises the activity of cysteine cathepsins: cathepsin S (CTSS; dominant in conventional DCs and B cells) and cathepsin L (CTSL; dominant in cortical thymic epithelial cells) progressively cleave Ii from the C-terminus, generating a series of Ii fragments and finally leaving only CLIP (amino acids 81–104) bound in the MHC-II groove. The resulting alphabeta-CLIP complex is stable enough to reach the cell surface but requires catalytic exchange.

HLA-DM and Peptide Exchange: Loading the Groove

HLA-DM (H-2M in mice) is a non-classical MHC-II-like molecule that acts as a peptide exchange catalyst in MIICs. HLA-DM transiently binds the alphabeta-CLIP complex, induces conformational changes that open the peptide-binding groove at the P1 pocket, destabilises the CLIP-groove interaction, and facilitates CLIP release. The same conformational openness enables incoming peptides — generated by cathepsin- mediated proteolysis of endocytosed antigens — to compete for binding. HLA-DM selectively stabilises high-affinity peptide-MHC II complexes: peptides that bind weakly are quickly removed by continued HLA-DM activity (kinetic proofreading of peptide-MHC affinity), while those that form stable interactions are released by HLA-DM and can traffic to the cell surface. HLA-DO (H-2O in mice) acts as a negative regulator of HLA-DM, particularly in B cells and thymic DCs, by binding DM and competing with alphabeta substrates, thereby raising the threshold for peptide editing. The net output of this MIIC processing machinery is a surface repertoire of pMHC-II complexes dominated by high-affinity, immunodominant peptides derived from endocytosed extracellular antigens, pathogens, or — in the tumour microenvironment — tumour-associated antigens processed by tumour-infiltrating DCs.

CIITA: The Master Transcriptional Regulator of MHC-II Expression

The class II transactivator (CIITA; MHC2TA) is a non-DNA-binding transcriptional co-activator that is both necessary and sufficient for MHC-II expression in virtually all cell types. CIITA does not bind DNA directly; instead, it assembles into a multiprotein enhanceosome (with NF-Y, RFX5, RFXAP, and RFXANK/RFX-B) on the conserved X1-X2-Y promoter elements of MHC-II genes. CIITA expression is controlled by three promoters: pI (constitutive in plasmacytoid DCs and monocytes), pIII (constitutive in B cells), and pIV (IFN-gamma-inducible in non-professional APCs and monocytes). IFN-gamma drives CIITA pIV expression through the JAK1/JAK2-STAT1 pathway: JAK2 phosphorylates STAT1 Tyr701, inducing STAT1 homodimerisation (gamma-activated factor; GAF), nuclear translocation, and binding to the GAS (gamma-activated sequence) element in the CIITA pIV promoter. IL-4 and IL-13 (Th2 cytokines) induce CIITA pIII in B cells and can upregulate surface MHC-II. TNF-alpha, paradoxically, can both upregulate MHC-II (via AP-1 on pIV) and suppress it (via NF-kappaB-mediated CIITA repression at high doses). CIITA is also a histone acetyltransferase-interacting protein, recruiting CBP/p300 and PCAF to the MHC-II promoter, linking MHC-II transcription to the acetyl-CoA epigenetic landscape.

Spirulina Polysaccharides, TLR Engagement, and DC Maturation

Immature dendritic cells are efficient at antigen capture (high macropinocytosis, receptor-mediated endocytosis) but poor at T cell priming (low surface MHC-II, co-stimulatory molecules CD80/CD86/CD83, and cytokines). DC maturation — triggered by pattern recognition receptor (PRR) activation — inverts this: lysosomal antigen processing accelerates (cathepsin activity peaks), MHC-II trafficking to the surface increases (new pMHC-II synthesis plus mobilisation of intracellular MIIC pools), and co-stimulatory molecules are upregulated to enable the three-signal T cell activation model (signal 1: pMHC-II+TCR; signal 2: CD80/CD86+CD28; signal 3: cytokines). Spirulina contains several immunoactive cell wall components with documented ability to engage PRRs. Calcium spirulan and other sulphated polysaccharides in the spirulina cell envelope engage TLR2 (recognises lipoteichoic acid-like structures and glycolipids) and, at higher concentrations, TLR4 (LPS pattern recognition). TLR2 and TLR4 signal through MyD88 (and TRIF for TLR4) to activate NF-kappaB and IRF3/IRF7, driving pro-inflammatory cytokine production. The most important consequence for antigen presentation is the downstream induction of IL-12p70 (a heterodimer of IL-12p35 + IL-12p40): IL-12 is the signature DC-derived cytokine that drives naive T helper cells (Th0) toward the Th1 lineage via STAT4 activation and T-bet induction. Multiple in vitro studies using spirulina extracts or isolated polysaccharides have documented enhanced IL-12 secretion from mouse and human DCs/macrophages, increased DC expression of CD80, CD86, and MHC-II surface density, and enhanced DC-driven T cell proliferation in mixed lymphocyte reactions. C-phycocyanin also appears to modulate DC function independently through its antioxidant effects on the DC's redox state during the oxidative burst of maturation, potentially fine-tuning cytokine outputs.

Th1/Th17 vs Treg Balance: Adaptive Immunity Priming Context

The cytokine environment produced by spirulina-matured DCs — particularly IL-12 and IL-6 — shapes which T helper subset will dominate the adaptive response. IL-12 + IFN-gamma (from NK cells activated by spirulina polysaccharides via NKG2D and ADCC pathways) drives Th1 differentiation (T-bet, IFN-gamma, TNF-alpha, strong cytotoxic CD8 T cell help — protective against intracellular pathogens and tumours). IL-6 + TGF-beta drives Th17 (RORgammat, IL-17A/F — protective against extracellular bacteria/fungi). TGF-beta alone (without IL-6) drives FoxP3⁺Treg induction. The net balance depends on the antigen context, spirulina dose, and pre-existing immune tone. The clinical relevance: in the context of allergic disease (Th2-dominant), spirulina's Th1-inducing capacity via IL-12 from activated DCs provides a mechanistic rationale for its documented IgE- lowering and anti-allergic rhinitis effects — the restored Th1/Th2 balance reduces IL-4/IL-13-driven IgE class switching in B cells. For immune surveillance against intracellular pathogens, spirulina's enhancement of DC maturation, IL-12 production, and MHC-II-mediated antigen presentation capacity collectively support more effective adaptive priming.

Practical Takeaways for Immune Function

The MHC-II antigen presentation pathway explains how the immune system translates encounter with a foreign antigen into a specific, high-affinity T helper cell response — and spirulina's TLR-mediated activation of dendritic cells sits at the input of this pathway. Enhanced DC maturation (more CD80/CD86, higher surface pMHC-II density, more IL-12) means a quantitatively and qualitatively better antigen presentation event. For practical immune support, this is most relevant during winter respiratory season, vaccine response optimisation, and recovery from immune-suppressive illness. One nuance: in autoimmune conditions where MHC-II-mediated presentation of self-peptides is already a disease driver (rheumatoid arthritis, multiple sclerosis, type 1 diabetes — all driven by HLA haplotype risk), further enhancement of DC maturation and MHC-II surface density is not desirable, and spirulina's immunomodulatory effects may be counterproductive or neutral depending on the specific context. For healthy individuals, the evidence supports spirulina as a mild but mechanistically grounded immune adjuvant whose primary mode of action on adaptive immunity is at the DC-T cell priming interface.